Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.

Casalino S, Scarlato E, Cruz MC, Gerdes C, Sordo A, Quinzii A, Zecchetto C, Messineo L, Tasselli E, Mendo L, Saborowski A, Bridgewater J, Vogel A, Melisi D.

Open source

DOI: 10.1016/j.ejca.2026.117036
Published: 2026-09-09
Container: Eur J Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117036,
  title = {Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.},
  author = {Casalino S and  Scarlato E and  Cruz MC and  Gerdes C and  Sordo A and  Quinzii A and  Zecchetto C and  Messineo L and  Tasselli E and  Mendo L and  Saborowski A and  Bridgewater J and  Vogel A and  Melisi D.},
  year = {2026},
  journal = {Eur J Cancer},
  doi = {10.1016/j.ejca.2026.117036},
  url = {https://doi.org/10.1016/j.ejca.2026.117036}
}

RIS

TY  - JOUR
TI  - Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.
AU  - Casalino S
AU  -  Scarlato E
AU  -  Cruz MC
AU  -  Gerdes C
AU  -  Sordo A
AU  -  Quinzii A
AU  -  Zecchetto C
AU  -  Messineo L
AU  -  Tasselli E
AU  -  Mendo L
AU  -  Saborowski A
AU  -  Bridgewater J
AU  -  Vogel A
AU  -  Melisi D.
PY  - 2026
JO  - Eur J Cancer
DO  - 10.1016/j.ejca.2026.117036
UR  - https://doi.org/10.1016/j.ejca.2026.117036
ER  -

APA

S, C., E, S., MC, C., C, G., A, S., A, Q., C, Z., L, M., E, T., L, M., A, S., J, B., A, V., & D., M. (2026). Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.. Eur J Cancer. https://doi.org/10.1016/j.ejca.2026.117036

Source records

europe-pmc · retrieved 2026-09-25T02:50:35.720Z